Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydroVax-002 YFV vaccine in healthy adults
NCT05172544Phase 1Completed
- Sponsor
- Najit Technologies, Inc.
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HydroVax-YFV in yellow fever, sponsored by Najit Technologies, Inc. Primary endpoints: Occurrence of All Serious Adverse Events, Occurrence of All Grade 3 Unsolicited Adverse Events and 4 more. Started Jan 2022; status: completed.
02
Drugs
HydroVax-YFV
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT05172544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172544.